1. A composition for treating diabetes, preferably type II diabetes, wherein said composition comprises:! (a) a virus-like particle (VLP) with at least one first attachment site； and! (b) at least one antigen with at least one second attachment site； ! wherein said at least one antigen comprises an IL-1 molecule and where (a) and (b) are linked through said at least one first and said at least one second attachment site, and where preferably said the IL-1 molecule is selected from the group consisting of: (a) mutein IL-1； (b) an IL-1 protein； (c) a mature fragment of IL-1； (d) a fragment of IL-1； and (e) peptide IL-1. ! 2. The composition of claim 1, wherein said IL-1 molecule is an IL-1 beta molecule comprising or preferably consisting of an amino acid sequence selected from the group consisting of:! (a) human IL-1 beta 117-269 (SEQ ID NO: 64)； ! (b) human IL-1 beta 116-269 (SEQ ID NO: 165)； ! (c) mouse IL-1 beta 119-269 (SEQ ID NO: 164)； and! (d) an amino acid sequence that is at least 80%, or preferably at least 90%, more preferably at least 95%, or most preferably at least 99% identical to any one of SEQ ID NO: 64, SEQ ID NO: 165 or SEQ ID NO: 164. ! 3. The composition according to claim 1, where the specified molecule of IL-1 is a mutein IL-1 beta, where preferably the specified mutein IL-1 beta comprises or preferably consists of a polypeptide, where the amino acid sequence of the polypeptide is different from the amino acid sequence of SEQ ID NO: 64 1-4 amino acid residues, and where also preferably decree1. Композиция для лечения диабета, предпочтительно диабета типа II, где указанная композиция включает: ! (a) вирусоподобную частицу (VLP), по крайней мере, с одним первым сайтом присоединения； и ! (b) по крайней мере, один антиген, по крайней мере, с одним вторым сайтом присоединения； ! где указанный, по крайней мере, один антиген включает молекулу IL-1 и где (а) и (b) являются связанными посредством указанного, по крайней мере, одного первого и указанног
